The therapeutic use of light, as we know it, begins in 1900 when Raab reported that the
combination of acridine orange and light could destroy living organisms (paramecium)[1]. In …

In photodynamic therapy, one of the problems limiting the use of many photosensitizers (PS)
is the difficulty in preparing pharmaceutical formulations that enable their parenteral …

Targeted photodynamic therapy (PDT) offers the opportunity of enhancing photodynamic
efficiency by directly targeting diseased cells and tissues. While antibody-conjugates have …

Photodynamic therapy (PDT) involves the combination of photosensitizers (PS) with light as
a treatment, and has been an established medical practice for about 10 years. Current …

Photodynamic therapy suffers from poor tumor selectivity and poor therapeutical efficacy. In
this paper, an amphiphilic chimeric peptide is fabricated to realize sequential acidity …

Photodynamic therapy (PDT) is a promising approach for the treatment of superficially
localized tumors. A limitation, however, is the lack of selectivity of the photosensitizers, which …

Photodynamic therapy (PDT) of malignant tumours is a new technique for treating cancers.
After intravenous injection, a photosensitiser is selectively retained by the tumour cells so …

Abstract Poly (3, 4‐ethylenedioxythiophene): poly (4‐styrenesulfonate)(PEDOT: PSS)
nanoparticles, after being coated with polyethylene glycol (PEG), are used as a drug carrier …

Photodynamic therapy (PDT) is a well‐established clinical treatment modality for various
diseases. However, reactive oxygen species (ROS) generated by photosensitizers (PS) …

It is recognized that chlorin e6–polyvinylpyrrolidone (Ce6–PVP) formulations are
characterized by a high efficacy in photodynamic therapy of malignant tumors. Currently, a …